Vir Biotechnology, Inc. (NASDAQ:VIR) Q2 2023 Earnings Conference Call August 3, 2023 4:30 PM ET

Company Participants

Sasha Damouni Ellis - EVP and Chief Corporate Affairs Officer

Marianne De Backer - CEO

Phil Pang - CMO

Sung Lee - CFO

Conference Call Participants

Gena Wang - Barclays

Paul Choi - Goldman Sachs

Roanna Ruiz - Leerink Partners

Eric Joseph - JPMorgan

Eva Privitera - TD Cowen

Mike Ulz - Morgan Stanley

Joseph Stringer - Needham & Company

Patrick Trucchio - H.C. Wainwright

Operator

Hello. Welcome to Vir Biotechnology Second Quarter 2023 Financial Results and Business Update Call. As a reminder, this conference call is being recorded. At this time, all participants are in a listen-only mode. After the speakers' presentation, there will be a question-and-answer session.

I will now turn the call over to Sasha Damouni Ellis, Executive Vice President, Chief Corporate Affairs Officer. You may begin Ms. Damouni Ellis.

Sasha Damouni Ellis

Thank you and good afternoon. With me today are Marianne De Backer, Chief Executive Officer; Dr. Phil Pang, Chief Medical Officer; and Sung Lee, Chief Financial Officer.

Before we begin, I would like to remind everyone that some of the statements we are making today are forward-looking statements under the securities laws. These forward-looking statements involve substantial risks and uncertainties that could cause our clinical development programs, future results, performance, or achievements to differ significantly from those expressed or implied by such forward-looking statements. These risks and uncertainties and risks associated with our business are described in the company's reports filed with the Securities and Exchange Commission, including Forms 10-K, 10-Q, and 8-K.

I will now turn the call over to our CEO, Marianne De Backer.

Marianne De Backer

Thank you, Sasha. Good afternoon and welcome to Vir Biotechnology's first earnings call. I'm Marianne De Backer, CEO of Vir, and I'm pleased to welcome you all here today.

I joined Vir four months ago, and every day since I'm reminded of how well Vir aligns with my commitment over the past 30 plus years to bring new medicines to patients.

Vir is one of those unique companies that uses ingenuity in the discovery of neutralizing antibody in the fight against COVID-19 and this during the very worst times of the pandemic. This was achieved in just 15 months and brought to nearly 2 million people around the world.

Before that, the Vir discovery engine had already yielded an antibody to treat Ebola. Now recognized by the World Health Organization for its impact.